Drug Safety in Post-FDAAA Era: An Epidemiologist's View
This article was originally published in RPM Report
Executive Summary
Bruce Psaty, longtime advocate of increased post-market safety controls for drugs, sees big challenges looming for FDA as it tries to adapt to the new authorities granted by the 2007 Food & Drug Administration Amendments Act. Psaty views the establishment of a large 100-million-life post-market surveillance system as a particularly daunting challenge.
You may also be interested in...
FDA Re-arms DSaRM: Recruits Eight Veterans from Safety/Surveillance World
The new group of Drug Safety & Risk Management Advisory Committee members comprises a lot of familiar faces. FDA has made use of its extensive outside academic connections, research grants and post-graduate training programs to bring in eight members for the Classes of 2013 and 2014. Most of them have been getting extensive on-the-job training with the advisory committee already.
IoM Will Address Ethics in Safety Studies Prior To Avandia Advisory Committees
FDA is acting to create political and scientific cover for the second public review of Avandia safety issues in mid-July. A former top staffer to House Energy & Commerce Chairman Waxman is doing an internal study of agency post-marketing safety procedures to assure Capitol Hill that FDA takes the issue seriously; an IoM workshop is convening in early June to prepare a preliminary review on the ethical issues with post-market safety studies.
IoM Will Address Ethics in Safety Studies Prior To Avandia Advisory Committees
FDA is acting to create political and scientific cover for the second public review of Avandia safety issues in mid-July. A former top staffer to House Energy & Commerce Chairman Waxman is doing an internal study of agency post-marketing safety procedures to assure Capitol Hill that FDA takes the issue seriously; an IoM workshop is convening in early June to prepare a preliminary review on the ethical issues with post-market safety studies.